Background: Elderly treated with dual antiplatelet therapy after percutaneous coronary intervention (PCI) represent a challenging population because of increased risk of both ischemic and bleeding events. We aimed to investigate the association between high on-treatment platelet reactivity (HPR) and long-term outcome in elderly with non-ST-elevated acute coronary syndromes (NSTE-ACS) undergoing PCI. Methods: Platelet reactivity was measured by vasodilator-stimulated phosphoprotein (VASP) assay at three time-points (baseline, discharge, 1 month after PCI) in 1053 NSTE-ACS patients (311 elderly) treated with clopidogrel. Major adverse cardiac events (MACE) were assessed up to 1 year-follow-up. Results: Elderly with HPR at discharge showed a significantly higher incidence of overall MACE (13 vs 4%, p =.006), cardiac death (6 vs 0.7%, p =.020), myocardial infarction (MI, 12 vs 4%, p =.031) and a trend for higher stent-thrombosis (5 vs 0.7%, p =.068). Similarly, elderly with 1-month-HPR showed between 1 month and 1 year significantly higher incidence of MACE (10 vs 4%, p =.012), cardiac death (6 vs 0.7%, p =.019) and composite cardiac death/MI (11 vs 4%, p =.014). Up to 1 year, elderly with HPR showed a 4-fold increased risk of MACE compared to both elderly without HPR (for discharge-HPR: p =.005; for 1-month-HPR: p =.01) and non-elderly with HPR (for discharge-HPR: p <.001; for 1-month-HPR: p <.0001). At multivariable analysis, HPR could independently predict 1-year-MACE in elderly (for discharge-HPR: HR = 3.191, CI: 1.373–7.417, p =.007; for 1-month-HPR: HR = 3.542, CI: 1.373–9.137, p =.009). Conclusions: In elderly with NSTE-ACS undergoing PCI and treated with clopidogrel, HPR was independently associated with an increased risk of MACE up to 1 year.

High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study / R. De Rosa, T. Palmerini, S. De Servi, M. Belmonte, G. Crimi, S. Cornara, P. Calabrò, M. Cattaneo, D. Maffeo, A. Toso, A. Bartorelli, C. Palmieri, M. De Carlo, D. Capodanno, P. Genereux, D. Angiolillo, F. Piscione, G. Galasso. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 259(2018), pp. 20-25. [10.1016/j.ijcard.2018.01.057]

High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study

S. Cornara;M. Cattaneo;A. Bartorelli;
2018

Abstract

Background: Elderly treated with dual antiplatelet therapy after percutaneous coronary intervention (PCI) represent a challenging population because of increased risk of both ischemic and bleeding events. We aimed to investigate the association between high on-treatment platelet reactivity (HPR) and long-term outcome in elderly with non-ST-elevated acute coronary syndromes (NSTE-ACS) undergoing PCI. Methods: Platelet reactivity was measured by vasodilator-stimulated phosphoprotein (VASP) assay at three time-points (baseline, discharge, 1 month after PCI) in 1053 NSTE-ACS patients (311 elderly) treated with clopidogrel. Major adverse cardiac events (MACE) were assessed up to 1 year-follow-up. Results: Elderly with HPR at discharge showed a significantly higher incidence of overall MACE (13 vs 4%, p =.006), cardiac death (6 vs 0.7%, p =.020), myocardial infarction (MI, 12 vs 4%, p =.031) and a trend for higher stent-thrombosis (5 vs 0.7%, p =.068). Similarly, elderly with 1-month-HPR showed between 1 month and 1 year significantly higher incidence of MACE (10 vs 4%, p =.012), cardiac death (6 vs 0.7%, p =.019) and composite cardiac death/MI (11 vs 4%, p =.014). Up to 1 year, elderly with HPR showed a 4-fold increased risk of MACE compared to both elderly without HPR (for discharge-HPR: p =.005; for 1-month-HPR: p =.01) and non-elderly with HPR (for discharge-HPR: p <.001; for 1-month-HPR: p <.0001). At multivariable analysis, HPR could independently predict 1-year-MACE in elderly (for discharge-HPR: HR = 3.191, CI: 1.373–7.417, p =.007; for 1-month-HPR: HR = 3.542, CI: 1.373–9.137, p =.009). Conclusions: In elderly with NSTE-ACS undergoing PCI and treated with clopidogrel, HPR was independently associated with an increased risk of MACE up to 1 year.
Clopidogrel; Elderly; Non-ST-elevated acute coronary syndromes; Platelet reactivity; Cardiology and Cardiovascular Medicine
Settore MED/09 - Medicina Interna
2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
De Rosa Int J Cardiol 2018 HPR in anziuani GEPRESS.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 624.49 kB
Formato Adobe PDF
624.49 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/572624
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 15
social impact